23 February 2022 – Race Oncology Limited (“Race”) is pleased to announce a researcherteam, led by Professor Borje Andersson and Associate Professor Ben Valdez of the MDAnderson Cancer Center (Texas, USA), have identified a number of additional clinicallytranslatable drug combinations…
31 January 2022 – Race Oncology Limited (“Race”) is pleased to announce theappointment of Christina Manfre, as Chief Financial Officer. Christina is employed as a partner at PKF Sydney Pty Ltd and will via PKF provideleadership to Race Oncology’s financial…
25 January 2022 – Race Oncology Limited (“Race”) is pleased is pleased to share details of a recent independent scientific publication in the journal Cells, confirming Zantrene® (bisantrene dihydrochloride) is a highly effective inhibitor of the Fat Mass and Obesity…
18 January 2022 – Race Oncology Limited (“Race”) is pleased to announce that it hasreceived a $707,557 Research & Development Tax Incentive Refund from the AustralianTaxation Office for the financial year ending 30 June 2021. Race’s Managing Director and CEO,…
